Parenteral Drugs Market Predicted to Reach Maximum Revenue and CAGR during 2019 to 2029

As the complexity of active pharmaceutical ingredients goes up, and includes small molecule options and biologics, the number of parenteral drugs has gone up as well. The number of new molecular products which have received the approval of regulatory bodies such as the FDA has gone up and has aided the growth of the industry for the foreseeable future. Major players in the parenteral drugs market are focusing their efforts on expanding their operations in terms of new countries to leverage opportunities in untapped markets, and also setting up new facilities for target markets. In a bid to secure a larger share of the market, manufacturers are also investing in the consolidation of extant production facilities.

Asia Pacific Being Targeted by Manufacturers

Major pharmaceutical companies from around the world are seeking the acquisition of smaller regional competitors, particularly those in the emerging markets of the Asia Pacific region, with the aim of maintaining sustainable rates of growth in terms of parenteral drugs. Further hospital pharmacies are gaining importance as primary channels of distribution owing to higher rates of hospitalization and the rising availability of requisitely skilled man power resources. Similar growth is also being projected for revenue being made by retail pharmacies.

Automation and Single Use Trends Support Rise

Single use strategies have been gaining traction in terms of proteins, antibodies, vaccines, cell therapy, and gene therapy processes. In addition, the FDA has been increasingly pushing for a higher rate of adoption of automation tech in the manufacturing of pharmaceuticals. On the other hand, adequately equipped automation technologies have not been developed for advanced products such as biologics, which is a key issue as manufacturers continue to raise the quality of their offerings.

You can Request an Example Copy from here –

Single use technologies allows easier maintenance of quality standards for biologics parenteral drugs, even as the overall market value is projected to reach USD 802 billion by the end of the forecast period in 2029.

Large Molecule Drugs and Biologics are Key to Demand

Monoclonal antibodies are expected to generate major revenue share in the parenteral drugs market owing to the rising number of approvals by regulatory bodies in recent times. In addition, large molecule parenteral drugs are also expected to experience an upward trajectory, as they are finding use in treatment of ailments such as blood disease, cancer, and diabetes. The higher use of large molecule formulations are also going up owing to the biocompatible nature of these drugs.

Ask Industry Professional about Report –

However, the industry is restricted owing to the high capital requirements for research and lengthy approval times. The parenteral drug industry is also witnessing increased spending on research and development, with most of the focus centering on oncology, owing to the vast patient pool, which is providing substantial growth opportunities for new drug launches of biologics, which are largely developed in injectable forms.

About FactMR

FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

Contact Us

11140 Rockville Pike
Suite 400, Rockville, MD 20852
United States

Matched content

Editor’s pick

Express Press Release Distribution